UCSF Helen Diller Family Comprehensive Cancer Center
Protocol Summary

[ Back to Protocol Listing ]

[ Print this page ]

Protocol No.13451Principal InvestigatorKo, Andrew
PhaseII (Cancer Control)
Age GroupAdultScopeNational
Secondary Protocol No.1208012946
TitleAn Open-Labeled, Multicenter Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma
ObjectiveTo demonstrate the antitumor activity as assessed by the rate of progression free survival at 3 months of Cabazitaxel IV every 3 weeks in subjects with previously treated metastatic gastroesophageal adenocarcinoma who are either taxane naive or taxance previously treated.
Key EligibilityAge: 18+ * Histologically or cytologically confirmed gastric, or gastroesophageal adenocarcinoma, or distal esophageal adenocarcinoma * Unresectable or metastatic gastroesophageal adenocarcinoma * Must have had at least one prior cytotoxic chemotherapy regimen for unresectable or metastatic disease
Applicable Disease SitesEsophagus
Stomach
StatusOpen
Participating InstitutionsMt. Zion
Eligibility Document13451_CTGovEligibility_NCT01757171.doc